Nordic Issuing

Ongoing case

Aptahem AB

Back to all cases

Aptahem AB

27 Aug - 10 Sep 2021Rights issue

Aptahem AB is a biotechnology company whose main business model is to preclinically and clinically develop aptamer-based treatments for life-threatening, acute conditions where coagulation and inflammation interact in the disease process. The aim is to meet the global need for medicines within these conditions.


Read more at the company's website

The offer in summary

Subscription period: 27 August - 10 September 2021

Subscription price: 4.80 SEK per unit

Trading in unit rights: 27 August - 7 September 2021

Issue volume: 61.8 MSEK

Unit: One (1) unit consists of four (4) shares and three (3) warrants of serie TO 7


Due to restrictions in applicable law in the United States, Canada, Australia, Hong Kong, Singapore, South Africa, Switzerland, New Zealand, Japan, Russia, Belarus or other countries where participation requires further prospectuses, registrations or actions other than those under Swedish law, the offer to subscribe for securities in this offer is not directed at persons or others with registered address in any of these countries.